NASDAQ$OPRX
OptimizeRx Corporation · Q3 2022 earnings
Q3 2022 earnings · · Investor relations
Briefing
OptimizeRx reported Q3 2022 financial results, with a focus on growth in Real World Evidence (RWE) solutions and reiteration of full-year financial outlook.
OptimizeRx reported its Q3 2022 financial results, highlighting momentum in Real World Evidence (RWE) solutions. The company reiterated its full-year financial outlook for net revenue between $62 million and $68 million and gross margins between 59% and 62%.
- OptimizeRx is seeing significant momentum off the mid-year trough.
- The company is gaining traction across its business, particularly with Real World Evidence (RWE) solutions.
- OptimizeRx believes executing on RWE opportunities could position them to grow topline by over 20% next year.
- The company reiterated its full-year financial outlook for 2022 for net revenue to be between $62 million and $68 million and gross margins to be between 59% and 62%.
Headline financials
Revenue & EPS history
OptimizeRx · Revenue · Quarterly
$15.1M
Forward guidance
OptimizeRx reiterated its full year 2022 financial outlook.
Tailwinds
- Net revenue to be between $62 million and $68 million.
- Year-over-year growth of 1% to 11%, respectively.
- Gross margins to be between 59% and 62%.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q3 2022
+1.3%
Avg return
Earnings day
+4.5%
Avg return
5 days after
+5.6%
Avg return
30 days after
55%
30 / 55 earnings
Positive
+51.7%
Q4 2024
Best reaction
-34.5%
Q2 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -22.6% | -19.7% | -17.5% | |
| Q4 2025 | -10.5% | -11.4% | -12.9% | |
| Q3 2025 | -17.0% | -14.7% | -24.8% | |
| Q1 2025 | +20.7% | +24.2% | +63.6% | |
| Q4 2024 | +51.7% | +99.8% | +96.4% | |
| Q3 2024 | -30.5% | -28.1% | -14.6% | |
| Q2 2024 | +1.2% | +4.5% | -8.9% | |
| Q1 2024 | +25.0% | +20.4% | +5.5% | |
| Q4 2023 | +13.6% | +4.9% | +20.1% | |
| Q3 2023 | +13.9% | +7.4% | +14.1% | |
| Q2 2023 | -29.3% | -32.6% | -38.9% | |
| Q1 2023 | -6.2% | -9.1% | +2.6% | |
| Q4 2022 | -14.2% | -25.0% | -14.5% | |
| Q3 2022 | +22.2% | +51.4% | +28.6% | |
| Q2 2022 | -34.5% | -31.6% | -33.4% | |
| Q1 2022 | -2.9% | -17.9% | -9.9% | |
| Q4 2021 | +14.0% | +2.4% | -5.5% | |
| Q3 2021 | -8.1% | -6.6% | -36.8% | |
| Q2 2021 | +20.9% | +16.0% | +27.7% | |
| Q1 2021 | +4.4% | -11.1% | +2.1% | |
| Q4 2020 | +0.8% | -0.2% | -17.4% | |
| Q3 2020 | +6.9% | +13.5% | +32.6% | |
| Q2 2020 | +11.0% | +10.2% | +21.8% | |
| Q1 2020 | +11.5% | +16.0% | +33.6% | |
| Q4 2019 | -26.0% | +3.6% | -36.8% | |
| Q3 2019 | -17.6% | -19.5% | -30.1% | |
| Q2 2019 | +2.6% | +0.8% | +13.9% | |
| Q1 2019 | +18.5% | +22.8% | +17.7% | |
| Q4 2018 | +1.1% | -0.2% | +22.6% | |
| Q3 2018 | -4.6% | -0.7% | -5.7% | |
| Q2 2018 | +15.9% | +23.4% | +26.7% | |
| Q1 2018 | +0.0% | +7.1% | +32.5% | |
| Q4 2017 | +0.0% | +10.7% | +14.5% | |
| Q3 2017 | +15.4% | +25.6% | +33.3% | |
| Q2 2017 | +16.4% | +9.1% | +15.5% | |
| Q1 2017 | +10.3% | +20.6% | +17.6% | |
| Q4 2016 | -10.6% | +7.9% | +1.3% | |
| Q3 2016 | -13.3% | +0.0% | -14.3% | |
| Q2 2016 | +0.9% | +0.0% | -3.5% | |
| Q4 2015 | +3.2% | — | — | |
| Q2 2015 | -3.2% | — | — | |
| Q4 2014 | +2.3% | — | — | |
| Q3 2014 | -4.3% | — | — | |
| Q2 2014 | +8.3% | — | — | |
| Q4 2012 | +11.2% | — | — | |
| Q2 2012 | +5.4% | — | — | |
| Q1 2012 | -10.4% | — | — | |
| Q4 2011 | +0.0% | — | — | |
| Q3 2011 | -1.9% | — | — | |
| Q2 2011 | +20.0% | — | — | |
| Q1 2011 | -15.2% | — | — | |
| Q4 2010 | +0.0% | — | — | |
| Q3 2010 | +15.0% | — | — | |
| Q2 2010 | -10.7% | — | — | |
| Q1 2010 | +1.6% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro